Intraperitoneal versus intravenous CPT-11 for peritoneal seeding and liver metastasis

被引:0
|
作者
Maruyama, M
Nagahama, T
Yuasa, Y
机构
[1] Tokyo Metropolitan Ohkubo Hosp, Dept Surg, Tokyo, Japan
[2] Tokyo Med & Dent Univ, Dept Hyg, Tokyo, Japan
关键词
CPT-11; liver metastasis; intraperitoneal chemotherapy;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: CPT-11 is an effective antitumor agent for gastrointestinal malignancy, but the optimum route of administration is unclear. Methods: Intraperitoneal administration of this agent was compared with intravenous administration in mouse models for peritoneal seeding and liver metastasis. The peritoneal seeding model and liver metastasis model were respectively established by inoculation of colon 26 tumor cells into the peritoneal cavity and spleen of female BALB/c mise. CPT-11 (40mg/kg) was injected intraperitoneally or intravenously on days 2 and 5 after inoculation of tumor cells. Results: Intraperitoneal administration of CPT-11 was significantly more effective than intravenous administration for control of both peritoneal seeding and liver metastasis. Conclusion: Intraperitoneal administration of CPT-11 may be a more efficient form of adjuvant chemotherapy for prevention of both peritoneal seeding and liver metastasis in patients with gastrointestinal cancer.
引用
收藏
页码:4187 / 4191
页数:5
相关论文
共 50 条
  • [21] Contribution of human liver carboxylesterase and human intestinal carboxylesterase to the activation of Irinotecan (CPT-11)
    Hatfield, Michael
    Tsurkan, Lyudmila
    Hicks, Latorya
    Hyatt, Janice
    Edwards, Carol
    Wierdl, Monika
    Potter, Philip
    CANCER RESEARCH, 2009, 69
  • [22] Conversion of the CPT-11 metabolite APC to SN-38 by rabbit liver carboxylesterase
    Guichard, SM
    Morton, CL
    Krull, EJ
    Stewart, CF
    Danks, MK
    Potter, PM
    CLINICAL CANCER RESEARCH, 1998, 4 (12) : 3089 - 3094
  • [23] Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver
    Tobin, PJ
    Hong, Y
    Seale, JP
    Rivory, LP
    McLachlan, AJ
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2005, 57 (01) : 39 - 45
  • [24] S-1 plus intravenous and intraperitoneal paclitaxel for gastric cancer with peritoneal metastasis
    Kitayama, J.
    Ishigami, H.
    Yamaguchi, H.
    Yamashita, H.
    Emoto, S.
    Kaisaki, S.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 : 264 - 264
  • [25] CPT-11 converting carboxylesterase and topoisomerase I activities in tumour and normal colon and liver tissues
    Guichard, S
    Terret, C
    Hennebelle, I
    Lochon, I
    Chevreau, P
    Frétigny, E
    Selves, J
    Chatelut, E
    Bugat, R
    Canal, P
    BRITISH JOURNAL OF CANCER, 1999, 80 (3-4) : 364 - 370
  • [26] CPT-11 converting carboxylesterase and topoisomerase I activities in tumour and normal colon and liver tissues
    S Guichard
    C Terret
    I Hennebelle
    I Lochon
    P Chevreau
    E Frétigny
    J Selves
    E Chatelut
    R Bugat
    P Canal
    British Journal of Cancer, 1999, 80 : 364 - 370
  • [27] Final results of phase III study of irinotecan (CPT-11) plus cisplatin (CDDP) versus vindesine (VDS) plus CDDP versus CPT-11 alone in advanced non-small cell lung cancer (NSCLC).
    Fukuoka, M
    Negoro, S
    Masuda, N
    Takada, Y
    Ohashi, Y
    ANNALS OF ONCOLOGY, 2000, 11 : 107 - 107
  • [28] Prolonged Deleterious influences of chemotherapeutic agent cPT-11 on resident Peritoneal Macrophages and B1 cells
    Bai, Wen-Jing
    Li, Chen-Guang
    Zhang, Cheng-Cheng
    Xu, Li-Hui
    Zeng, Qiong-Zhen
    Hu, Bo
    Hong, Zhou
    He, Xian-Hui
    Ouyang, Dong-Yun
    FRONTIERS IN IMMUNOLOGY, 2018, 8
  • [29] Isolation and characterization of a cDNA encoding a horse liver butyrylcholinesterase - Evidence for CPT-11 drug activation
    Wierdl, M
    Morton, CL
    Danks, MK
    Potter, PM
    BIOCHEMICAL PHARMACOLOGY, 2000, 59 (07) : 773 - 781
  • [30] Sensitization of human tumor cells to CPT-11 by adenoviral-mediated delivery of a rabbit liver carboxylesterase
    Wierdl, M
    Morton, CL
    Weeks, JK
    Danks, MK
    Harris, LC
    Potter, PM
    CANCER GENE THERAPY, 2000, 7 (12) : S22 - S22